BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Talecris Biotherapeutics Study Demonstrates Aerosolized Prolastin(R) Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs


9/18/2007 11:47:33 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. (http://www.talecris.com) presented new data today at the 2007 Annual Congress of the European Respiratory Society (ERS) demonstrating that using the AKITA2® APIXNEB® system (Activaero Technologies) to inhale Prolastin® (Alpha-1 Proteinase Inhibitor [Human]) results in very high levels of drug deposited in the central and peripheral regions of the lungs. The clinical study data demonstrated that distribution in patients with alpha-1 antitrypsin (AAT) deficiency and cystic fibrosis who had moderate to severe lung function impairment was similar to levels achieved in healthy subjects.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->